By evaluating survival and treatment outcomes in a mouse model of pancreatic cancer, we identified that CNT1 deficiency led to reduced antitumor drug efficacy, resulting in accelerated mortality. This evidence concerns the gene SLC28A1 and pancreatic neoplasm.